Research programme: pain therapy - Merck/Banyu

Drug Profile

Research programme: pain therapy - Merck/Banyu

Alternative Names: Comp B; J 113397

Latest Information Update: 29 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Banyu; Merck & Co
  • Class Benzimidazoles; Piperidines; Small molecules
  • Mechanism of Action Nociceptin receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pain; Traumatic stress disorders

Most Recent Events

  • 29 Aug 2011 No development reported - Preclinical for Pain in Japan (SC)
  • 29 Aug 2011 No development reported - Preclinical for Stress disorders in Japan (IV)
  • 19 Nov 2008 Preclinical trials in Stress disorders in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top